Cytokinetics, Incorporated (Nasdaq: CYTK) will provide an update on the company's cardiac myosin modulation programs and ...

Respiratory syncytial virus (RSV) remains the top cause of hospitalization among young children, leading to respiratory ...

The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.

Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in ...

Catheter ablation is associated with significant reductions in AF symptoms, AF-related hospitalization, and HF symptoms across HF subtypes.

Cardiovascular disease, sometimes abbreviated as CVD, is the leading cause of death worldwide. It’s a catchall term for heart ...

USA: A recent study from the EMBARK-HFpEF trial has revealed promising results regarding using mavacamten, a cardiac myosin ...

Postmarket data on MitraClip lend further support to the idea that this subgroup fares as well as the overall SMR population.

HFpEF is most common among older adults and women. This article discusses the symptoms, causes, diagnosis, and treatment of heart failure with preserved ejection fraction. If you have HFpEF, your ...

Cardiac arrhythmias can produce a range of symptoms—from very mild, like lightheadedness, to life-threatening, including cardiac arrest. These can be divided into a “classic” group of symptoms that ...

After 19 weeks on daily oral HU6 treatment, people shed on average 2.9 kg (~6.3 lb) or 2.7% of their starting body weight relative to placebo, both significant changes supporting some efficacy of the ...